iwCLL 2019 | Highlights from iwCLL 2019: MRD and novel therapies
Lydia Scarfò and William Wierda
• 22 Sep 2019
William Wierda, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, and Lydia Scarfo, MD, from Vita-Salute San Raffaele University, Milan, Italy, discuss the utility of MRD as an intermediate endpoint in chronic lymphocytic leukemia (CLL) treatment. The speakers touch on immuno-chemotherapy and novel therapies introduced at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
